Register here for the next investor webinar (27th Feb) with Sovereign Metals (SVML), Europa Oil & Gas (EOG) and Microsalt (SALT).
@estura, you wrote: "Not sure why therefore I should have to explain my personal view that a placing is coming (which it is), but I am saying confidently that it is important to get it out the way asap".
First you state it is your personal view and then you immediately say it is a fact. Which is it? Or rather, is it BS or insider information?
Many many ways for a small pharma company to raise capital and all options will be explored. Avacta is fortunate to have many assets and a cash-generative division.
Basically, these FUDsters don't understand the pharma industry and think Avacta's business model is the same as Wilko's. Basically the FUDsters are 🤡🤡, 🤠🤠 and 💩sters.
The biggest nothing has changed is that Arm 2 still doesn't have a complete first cohort FIVE MONTHS after announcing the intention to do it and at least TEN WEEKS and likely much longer since screening began. WHY?
When they say that patients in the Arm 2 cohorts will have FAPhigh cancers, I don't think many connected that with the Dx slide having been pulled when the DX overview was being given last year.
A patentee has one year in which to file patent applications around the rest of the world after the first application (the priority application on the priority date) has been filed. These additional applications would typically be made on the last day before the year was up in order to claim the longest possible patent protection. However public disclosure of the invention by any means at any time during that year would invalidate those additional applications.
This doesn't use CanSEEK. PNT6555 is a version of PNT2004. The Lu version is in Phase 1, the Ac version still in preclinical.
Addendum: and not only "subconsciously assume that everyone knows what they know", but also, when proofreading, gloss over the text reading what they expect to see there rather than the text that is actually there.
☝️ A point that immediately occurred to me after rereading what I had just posted and noting errors I missed when checking before posting...
@DTW, I agree that holding updates would be a bad idea, and would just cause more uncertainty and opportunities for FUD.
For me, the problem lies in the incompleteness and ambiguity in the RNS's that ARE released. I suspect that these are created and proof-read by experts who, due to their complete knowledge of the project, subconsciously assume that everyone knows what they know. If they were to give TX RNS's to a couple of DX people (being scientists somewhat removed from the action) to read over they would soon unearth and point out the omissions, inconsistencies and ambiguities. Such a simple thing to do!
If Myles McNulty is meeting management with a set of questions, that would be an excellent way for Avacta kickstart their blog that they agreed (at when was it? Science Day? AGM?) would be a good communication channel. In fact, I'd say it was vital that Avacta do that. Let AS et al write up the responses and post on the Avacta website for all to read. Kills many birds with one stone.
The patients don't want to take an experimental treatment ahead of the SoC.
The clinicians are taking patients for other drug trials.
The selection criteria are too narrow to find the treatment-naive patients they want and they don't want to fill the cohort with pretreated patients.
The US healthcare system is a serious roadblock for this type of trial.
Avacta has totally misjudged the time needed to recruit patients.
Or they could just be writing the RNS blurb from scratch each time rather than using the time saving method of having standard, agreed and approved texts that can just be slotted in as needed. Wouldn't surprise me given the way this company goes about things.
I'm absolutely convinced the board knows what coming. The question is "What is coming?"
We shouldn't forget that article on 'telltale signs your company is about to be taken over' - top management staff who will have no role in the new organisation leaving for other jobs and the company not doing anything to support a continually falling share price that will make the modest takeover premium seem a bargain to traders and frustrated, demoralised investors alike.
And all the while, the silence from the company is deafening.
Working on a first approximation of the mid market price being 95p:
9,515 x 95p = £9,039.25
So 3 employees got £3,000 or some combination of more employees getting less each.
It's the bonus for top management? For a project team? A little for a lot of staff? No big deal.
Also gotta say, not the RNS I was hoping for.